| Target Professions: | DO, MD, Nurse, Nurse Practitioner, Physician Assistant |
| Target Specialties: | Pediatrics, Neurology, Orthopedic Medicine/Sports Medicine, Physiatry/Rehabilitation |
| Credits Available: | 4.75 AMA PRA Category 1 Credit™ & 4.75 MOC points |
The goal of this initiative is to improve the care of patients with Duchenne muscular dystrophy (DMD). DMD is the most common childhood form of muscular dystrophy and characteristic manifestations are progressive muscle weakness, cardiorespiratory impairment, and premature death. Gene therapy provides a new avenue to treat life‐limiting neuromuscular disorders. Given the novelty of these therapies, clinicians involved in the care of patients with DMD may not be aware of their associated evidence and implementation. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with Duchenne muscular dystrophy.
The following questions are designed to assess your knowledge and practice of patients with Duchenne muscular dystrophy.
This module focuses on the understanding of recent advancements in gene therapy, provide a clear interpretation of the most current clinical trial results, and consider their implications for patient care.
This module focuses on the key laboratory monitoring required after gene transfer, the need for high-dose corticosteroids before and after transfer, and the management of common and serious adverse events (AEs).
This module focuses on how to engage in effective shared decision-making when considering gene therapies, while factoring patient/caregiver specific factors as well as barriers to equitable care in DMD.
The following questions are designed to assess your gained knowledge and practice of patients with Duchenne muscular dystrophy.
During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with Duchenne muscular dystrophy.
During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with Duchenne muscular dystrophy.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with Duchenne muscular dystrophy (DMD).
During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.
